[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals (VRTX) Falls More Steeply Than Broader Market: What Investors Need to Know",
    "summary": "In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $469.29, indicating a -0.99% shift from the previous trading day.",
    "url": "https://finnhub.io/api/news?id=56e8287421bea4c8cefd0cbbeef529a1f648e53ac80fcf1b9d7c96e915d83e21",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733871011,
      "headline": "Vertex Pharmaceuticals (VRTX) Falls More Steeply Than Broader Market: What Investors Need to Know",
      "id": 131919410,
      "image": "https://media.zenfs.com/en/zacks.com/023168c7ea091c342492be3899b280af",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $469.29, indicating a -0.99% shift from the previous trading day.",
      "url": "https://finnhub.io/api/news?id=56e8287421bea4c8cefd0cbbeef529a1f648e53ac80fcf1b9d7c96e915d83e21"
    }
  },
  {
    "ts": null,
    "headline": "uniQure's AMT-130: A Bold Step For Huntington's, But Not Without Hurdles",
    "summary": "uniQure's AMT-130 shows promising results for Huntingtonâs disease. Learn why QURE stock faces commercialization challenges despite strong clinical data.",
    "url": "https://finnhub.io/api/news?id=812e8ba0e02bb9107297dc8e8a1a78dec96110cd1e72c5bf03ecf029a2c38e56",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733851246,
      "headline": "uniQure's AMT-130: A Bold Step For Huntington's, But Not Without Hurdles",
      "id": 131909069,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1277345854/image_1277345854.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "uniQure's AMT-130 shows promising results for Huntingtonâs disease. Learn why QURE stock faces commercialization challenges despite strong clinical data.",
      "url": "https://finnhub.io/api/news?id=812e8ba0e02bb9107297dc8e8a1a78dec96110cd1e72c5bf03ecf029a2c38e56"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
    "summary": "Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=9bfb9732f31743c21c5f281ad044d570ae22131dacde6026ca6d4b12636a2eb2",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733848860,
      "headline": "Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
      "id": 131936104,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=9bfb9732f31743c21c5f281ad044d570ae22131dacde6026ca6d4b12636a2eb2"
    }
  }
]